Masaki Ishida

7PUBLICATIONS
35CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 05, 2026
Protocol of a Real-World Prospective Observational Study of Amivantamab Plus Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (SPIRAL-RACER20 Study).

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Jul 23, 2024
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.

Yohei Matsui, Tadaaki Yamada, Yuki Katayama

|Mar 07, 2024
Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.

Masaki Ishida, Masahiro Iwasaku, Toshifumi Doi

|Oct 06, 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Soichi Hirai, Tadaaki Yamada, Yuki Katayama

|Mar 03, 2023
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.

Tae Hata, Chikara Sakaguchi, Keita Hirano

Pageof 2

Frequent Collaborators

7 joint publications

Tadaaki Yamada

3 joint publications

Kenji Morimoto

3 joint publications

Takayuki Takeda

3 joint publications

Koichi Takayama